Individuals living with von Willebrand Disease (VWD) often face frequent bleeding and lower quality of life. BCDI Associate Medical/Research Director, Dr. Jonathan Roberts, led a real-world study across 11 U.S. Hemophilia Treatment Centers in a new article published in the May 2025 edition of Expert Review of Hematology.

This latest study shows that routine prophylaxis with recombinant von Willebrand factor (rVWF) significantly reduced bleeding episodes, as well as outpatient and hospital visits across all VWD subtypes, especially when compared to prior VWD treatments.

To read this new study from Dr. Roberts, entitled “Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States” click here!